

This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.

This English version is intended to be a reference material to provide convenience for users.

In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revision of PRECAUTIONS

Clarithromycin

March 17, 2026

Therapeutic category

Antibiotic preparations acting mainly on gram-positive bacteria and mycoplasma

Non-proprietary name

Clarithromycin

Safety measure

PRECAUTIONS should be revised.

This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.
 This English version is intended to be a reference material to provide convenience for users.
 In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revised language is underlined.

Current	Revision											
<p>2. CONTRAINDICATIONS (This drug is contraindicated to the following patients.)</p> <p>Patients receiving pimozide, ergotamine tartrate/anhydrous caffeine/isopropylantipyrine, dihydroergotamine mesilate, suvorexant, daridorexant hydrochloride, vornorexant hydrate, lomitapide mesilate, tadalafil (Adcirca), ticagrelor, ibrutinib, ivabradine hydrochloride, venetoclax (relapsed or refractory chronic lymphocytic leukaemia [including small lymphocytic lymphoma] and relapsed or refractory mantle cell lymphoma during the dose escalation phase), lurasidone hydrochloride, anamorelin hydrochloride, finerenone, isavuconazonium sulfate, voclosporin, <u>or</u> mavacamten</p> <p>10. INTERACTIONS</p> <p>10.1 Contraindications for Co-administration (Do not co-administer with the following.)</p> <p>(N/A)</p>	<p>2. CONTRAINDICATIONS (This drug is contraindicated to the following patients.)</p> <p>Patients receiving pimozide, ergotamine tartrate/anhydrous caffeine/isopropylantipyrine, dihydroergotamine mesilate, suvorexant, daridorexant hydrochloride, vornorexant hydrate, lomitapide mesilate, tadalafil (Adcirca), ticagrelor, ibrutinib, ivabradine hydrochloride, venetoclax (relapsed or refractory chronic lymphocytic leukaemia [including small lymphocytic lymphoma] and relapsed or refractory mantle cell lymphoma during the dose escalation phase), lurasidone hydrochloride, anamorelin hydrochloride, finerenone, isavuconazonium sulfate, voclosporin, mavacamten, <u>azelnidipine, or olmesartan medoxomil/azelnidipine</u></p> <p>10. INTERACTIONS</p> <p>10.1 Contraindications for Co-administration (Do not co-administer with the following.)</p> <table border="1" data-bbox="1133 1115 2000 1398"> <thead> <tr> <th data-bbox="1133 1115 1473 1214">Drugs</th> <th data-bbox="1473 1115 1762 1214">Signs, symptoms, and treatment</th> <th data-bbox="1762 1115 2000 1214">Mechanism/risk factors</th> </tr> </thead> <tbody> <tr> <td data-bbox="1133 1214 1473 1404"><u>Azelnidipine</u></td> <td data-bbox="1473 1214 1762 1404"><u>The blood</u></td> <td data-bbox="1762 1214 2000 1404"><u>The CYP3A</u></td> </tr> <tr> <td data-bbox="1133 1276 1473 1404"><u>Olmesartan medoxomil/azelnidipine</u></td> <td data-bbox="1473 1276 1762 1404"><u>concentration of azelnidipine may increase, and its</u></td> <td data-bbox="1762 1276 2000 1404"><u>inhibitory activity of clarithromycin may suppress</u></td> </tr> </tbody> </table>			Drugs	Signs, symptoms, and treatment	Mechanism/risk factors	<u>Azelnidipine</u>	<u>The blood</u>	<u>The CYP3A</u>	<u>Olmesartan medoxomil/azelnidipine</u>	<u>concentration of azelnidipine may increase, and its</u>	<u>inhibitory activity of clarithromycin may suppress</u>
Drugs	Signs, symptoms, and treatment	Mechanism/risk factors										
<u>Azelnidipine</u>	<u>The blood</u>	<u>The CYP3A</u>										
<u>Olmesartan medoxomil/azelnidipine</u>	<u>concentration of azelnidipine may increase, and its</u>	<u>inhibitory activity of clarithromycin may suppress</u>										

This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.

This English version is intended to be a reference material to provide convenience for users.

In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

		<u>effects may be enhanced.</u>	<u>the metabolism of these drugs, leading to an increase in their blood concentration.</u>
--	--	---------------------------------	--

N/A: Not Applicable. No corresponding language is included in the current PRECAUTIONS.